Claro Advisors LLC Trims Position in Moderna, Inc. (NASDAQ:MRNA)

Claro Advisors LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA) by 17.4% during the 4th quarter, HoldingsChannel reports. The firm owned 5,627 shares of the company’s stock after selling 1,184 shares during the period. Claro Advisors LLC’s holdings in Moderna were worth $234,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna in the 2nd quarter worth approximately $26,000. Itau Unibanco Holding S.A. purchased a new stake in Moderna during the second quarter valued at approximately $75,000. Blue Trust Inc. raised its position in Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the period. Larson Financial Group LLC grew its position in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. Finally, Rakuten Securities Inc. increased its stake in shares of Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Moderna stock opened at $34.77 on Thursday. Moderna, Inc. has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average is $41.44 and its 200 day moving average is $67.56. The company has a market cap of $13.38 billion, a price-to-earnings ratio of -5.97 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) EPS. Sell-side analysts forecast that Moderna, Inc. will post -9.3 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 2,664 shares of company stock worth $115,210 over the last ninety days. Company insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MRNA shares. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Sanford C. Bernstein started coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Jefferies Financial Group decreased their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $76.68.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.